Gilead Sciences, Inc. - Significant Ownership

Signature - Title
/s/ Andrew D. Dickinson - Andrew D. Dickinson, Executive Vice President and Chief Financial Officer
Location
Foster City, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Gilead Sciences, Inc..

Significant Ownership of Gilead Sciences, Inc.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GLPG Galapagos NV Ordinary Shares, no par value 29.9% $493M 21M Gilead Sciences, Inc. Jan 7, 2025
ASMB ASSEMBLY BIOSCIENCES, INC. Common Stock, par value $0.001 29% 4.51M +104% GILEAD SCIENCES, INC. Aug 8, 2025
RCUS Arcus Biosciences, Inc. Common Stock, par value $0.0001 25.6% $427M 31.4M 0% GILEAD SCIENCES, INC. Nov 3, 2025
XLO Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share 19.9% $7.32M $1.04M 10.6M +16.6% GILEAD SCIENCES, INC. Jun 30, 2025
KLRS Kalaris Therapeutics, Inc. Common Stock, $0.0001 per value 3.9% $5.81M 723K GILEAD SCIENCES, INC. Mar 18, 2025
IKNA Ikena Oncology, Inc. Common Stock 3.6% $1.61M 1.52M GILEAD SCIENCES INC Dec 31, 2024

Schedules 13D/G Reported by Gilead Sciences, Inc.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.